吉非替尼一线治疗晚期非小细胞肺癌的临床研究  

Clinical study of gefitinib in the first line treatment of patients with advanced non-small-cell lung

作　　者：冯连杰[1] 张庆富[1] 何志杰[1] 申静[1] 魏涛[1] 

机构地区：[1]河南省安阳市肿瘤医院放疗三科,455000

出　　处：《中国实用医刊》2012年第11期48-50,共3页Chinese Journal of Practical Medicine

摘　　要：目的评价吉非替尼一线治疗晚期非小细胞肺癌（NSCLC）的疗效及不良反应。方法58例晚期NSCLC患者接受吉非替尼250mg／d治疗，连续用药至疾病进展或出现严重的不良反应。治疗2个月后进行疗效和不良反应分析。河南省安阳市肿瘤医院放疗三科同时对58例患者的肿瘤标本进行表皮生长因子受体（EGFR）基因状态检测。结果58例患者中完全缓解2例（3．4％），部分缓解16例（27．6％），疾病稳定24例（41．4％），疾病进展16例（36．5％），疾病控制率为72．4％。单因素分析结果显示临床获益和性别、组织学类型、吸烟史、EGFR突变状态显著相关（P〈0．05），而与临床分期无关。58例标本中30例EGFR为突变型。EGFR的突变率为51．7％。结论吉非替尼一线治疗NSCLC疗效较好，耐受性良好，可明显改善症状，提高患者生活质量。Objective To evaluate the clinical efficacy and toxicity of gefitinib in the first line treatment of patients with advanced non-small-cell lung cancer （NSCLC）. Methods Fifty-eight NSCLC patients were treated with gefitinib 250 mg orally taken once daily until disease progression or the occurrence of intolerablet toxicity. After two months＇ treatment, the clinical efficacy and toxicity were analyzied. Synchronously, the EGFR mutation status of tumor samples was detected. Results Among these 58 patients, there were 2 cases with CR（3.4% ）, 16 cases with PR（27.6% ）, 24 cases with SD（41.4% ）, 16 cases with PD（36. 5% ）. The disease control rate was 72. 4%. The clinical benefit rate was significantly correlated with gender, pathologic type, smoking history and the status of EGFR, but not with clinical stage. The mutation rates of EGFR was 51.7% （30/58）. Conclusions In the first line treatment of patients with advanced NSCLC, gefitinib is effective and safe which can relieve symptom and improve the quality of the life.

关 键 词：吉非替尼 非小细胞肺癌 表皮生长因子受体 分子靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]